Matches in Nanopublications for { ?s ?p "[Crizotinib, a dual anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor, is currently being evaluated for the treatment of neuroblastoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- assertion description "[Crizotinib, a dual anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor, is currently being evaluated for the treatment of neuroblastoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Crizotinib, a dual anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor, is currently being evaluated for the treatment of neuroblastoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_assertion description "[Crizotinib, a dual anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor, is currently being evaluated for the treatment of neuroblastoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP235729.RAAuFEXrhDVWmWV9lAMuSQzUOthLBL-Ui0YCfi8AupCAQ130_provenance.
- NP235488.RAppibt0v1IQMHPooiNCKPf5CSBwMyJso38rbqQpw6zL4130_assertion description "[Crizotinib, a dual anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor, is currently being evaluated for the treatment of neuroblastoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP235488.RAppibt0v1IQMHPooiNCKPf5CSBwMyJso38rbqQpw6zL4130_provenance.
- NP1089086.RAv-8THKv6PjZvxgo5lJRwjDBFzl0cFzBI0Po02TzLrbQ130_assertion description "[Crizotinib, a dual anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor, is currently being evaluated for the treatment of neuroblastoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1089086.RAv-8THKv6PjZvxgo5lJRwjDBFzl0cFzBI0Po02TzLrbQ130_provenance.
- NP1089087.RAuXbTMPd3yoGW6TxAb1cRWjJYOCepK79_pRXYX7yaRmQ130_assertion description "[Crizotinib, a dual anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor, is currently being evaluated for the treatment of neuroblastoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1089087.RAuXbTMPd3yoGW6TxAb1cRWjJYOCepK79_pRXYX7yaRmQ130_provenance.